|
|
J Clin Invest. 1993 September; 92(3): 1262–1268. doi: 10.1172/JCI116698. | PMCID: PMC288266 |
X-linked nephrogenic diabetes insipidus mutations in North America and the Hopewell hypothesis. D G Bichet, M F Arthus, M Lonergan, G N Hendy, A J Paradis, T M Fujiwara, K Morgan, M C Gregory, W Rosenthal, A Didwania , et al.Unité de Recherche Clinique, Hôpital du Sacré-Coeur, Montréal, Québec, Canada. Abstract In X-linked nephrogenic diabetes insipidus (NDI) the urine of male patients is not concentrated after the administration of the antidiuretic hormone arginine-vasopressin. This disease is due to mutations in the V2 receptor gene that maps to chromosome region Xq28. In 1969, Bode and Crawford suggested that most NDI patients in North America shared common ancestors of Ulster Scot immigrants who arrived in Halifax in 1761 on the ship Hopewell. A link between this family and a large Utah kindred was also suggested. DNA was obtained from 17 affected male patients from the "Hopewell" kindred and from four additional families from Nova Scotia and New Brunswick who shared the same Xq28 NDI haplotype. The Utah kindred and two families (Q2, Q3) from Quebec were also studied. The "Hopewell" mutation, W71X, is a single base substitution (G-->A) that changes codon 71 from TGG (tryptophan) to TGA (stop). The W71X mutation was found in affected members of the Hopewell and of the four satellite families. The W71X mutation is the cause of X-linked NDI for the largest number of related male patients living in North America. Other families (Utah, Q2 and Q3) that are historically and ethnically unrelated bear other mutations in the V2 receptor gene. Full text Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.2M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References. Images in this article Click on the image to see a larger version. These references are in PubMed. This may not be the complete list of references from this article. - Forssman H. The recognition of nephrogenic diabetes insipidus. A very small page from the history of medicine. Acta Med Scand. 1975 Jan–Feb;197(1-2):1–6. [PubMed]
- Knoers N, van der Heyden H, van Oost BA, Monnens L, Willems J, Ropers HH. Three-point linkage analysis using multiple DNA polymorphic markers in families with X-linked nephrogenic diabetes insipidus. Genomics. 1989 Apr;4(3):434–437. [PubMed]
- Bode HH, Crawford JD. Nephrogenic diabetes insipidus in North America. The Hopewell hypothesis. N Engl J Med. 1969 Apr 3;280(14):750–754. [PubMed]
- CANNON JF. Diabetes insipidus; clinical and experimental studies with consideration of genetic relationships. AMA Arch Intern Med. 1955 Aug;96(2):215–272. [PubMed]
- Bichet DG, Hendy GN, Lonergan M, Arthus MF, Ligier S, Pausova Z, Kluge R, Zingg H, Saenger P, Oppenheimer E, et al. X-linked nephrogenic diabetes insipidus: from the ship Hopewell to RFLP studies. Am J Hum Genet. 1992 Nov;51(5):1089–1102. [PubMed]
- Bianchine JW, Stambler AA, Harrison HE. Nephrogenic (vasopressin-resistant) diabetes insipidus with the usual X-linked inheritance. Birth Defects Orig Artic Ser. 1971 May;7(6):280–281. [PubMed]
- Feigin RD, Rimoin DL, Kaufman RL. Nephrogenic diabetes insipidus in a Negro kindred. Am J Dis Child. 1970 Jul;120(1):64–68. [PubMed]
- Libber S, Harrison H, Spector D. Treatment of nephrogenic diabetes insipidus with prostaglandin synthesis inhibitors. J Pediatr. 1986 Feb;108(2):305–311. [PubMed]
- Schultz P, Lines DR. Nephrogenic diabetes insipidus in an Australian aboriginal kindred. Humangenetik. 1975;26(1):79–85. [PubMed]
- Kambouris M, Dlouhy SR, Trofatter JA, Conneally PM, Hodes ME. Localization of the gene for X-linked nephrogenic diabetes insipidus to Xq28. Am J Med Genet. 1988 Jan;29(1):239–246. [PubMed]
- van den Ouweland AM, Knoop MT, Knoers VV, Markslag PW, Rocchi M, Warren ST, Ropers HH, Fahrenholz F, Monnens LA, van Oost BA. Colocalization of the gene for nephrogenic diabetes insipidus (DIR) and the vasopressin type 2 receptor gene (AVPR2) in the Xq28 region. Genomics. 1992 Aug;13(4):1350–1352. [PubMed]
- van den Ouweland AM, Dreesen JC, Verdijk M, Knoers NV, Monnens LA, Rocchi M, van Oost BA. Mutations in the vasopressin type 2 receptor gene (AVPR2) associated with nephrogenic diabetes insipidus. Nat Genet. 1992 Oct;2(2):99–102. [PubMed]
- Jans DA, van Oost BA, Ropers HH, Fahrenholz F. Derivatives of somatic cell hybrids which carry the human gene locus for nephrogenic diabetes insipidus (NDI) express functional vasopressin renal V2-type receptors. J Biol Chem. 1990 Sep 15;265(26):15379–15382. [PubMed]
- Birnbaumer M, Seibold A, Gilbert S, Ishido M, Barberis C, Antaramian A, Brabet P, Rosenthal W. Molecular cloning of the receptor for human antidiuretic hormone. Nature. 1992 May 28;357(6376):333–335. [PubMed]
- Lolait SJ, O'Carroll AM, McBride OW, Konig M, Morel A, Brownstein MJ. Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature. 1992 May 28;357(6376):336–339. [PubMed]
- Sharif M, Hanley MR. Peptide receptors. Stepping up the pressure. Nature. 1992 May 28;357(6376):279–280. [PubMed]
- Pan Y, Metzenberg A, Das S, Jing B, Gitschier J. Mutations in the V2 vasopressin receptor gene are associated with X-linked nephrogenic diabetes insipidus. Nat Genet. 1992 Oct;2(2):103–106. [PubMed]
- Seibold A, Brabet P, Rosenthal W, Birnbaumer M. Structure and chromosomal localization of the human antidiuretic hormone receptor gene. Am J Hum Genet. 1992 Nov;51(5):1078–1083. [PubMed]
- Rosenthal W, Seibold A, Antaramian A, Lonergan M, Arthus MF, Hendy GN, Birnbaumer M, Bichet DG. Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus. Nature. 1992 Sep 17;359(6392):233–235. [PubMed]
- WALKER NF, RANCE CP. Inheritance of nephrogenic diabetes insipidus. Am J Hum Genet. 1954 Sep;6(3):354–358. [PubMed]
- Bichet DG, Razi M, Lonergan M, Arthus MF, Papukna V, Kortas C, Barjon JN. Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. N Engl J Med. 1988 Apr 7;318(14):881–887. [PubMed]
- Bichet DG, Razi M, Arthus MF, Lonergan M, Tittley P, Smiley RK, Rock G, Hirsch DJ. Epinephrine and dDAVP administration in patients with congenital nephrogenic diabetes insipidus. Evidence for a pre-cyclic AMP V2 receptor defective mechanism. Kidney Int. 1989 Nov;36(5):859–866. [PubMed]
- Tsui LC. Mutations and sequence variations detected in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: a report from the Cystic Fibrosis Genetic Analysis Consortium. Hum Mutat. 1992;1(3):197–203. [PubMed]
- Savarese TM, Fraser CM. In vitro mutagenesis and the search for structure-function relationships among G protein-coupled receptors. Biochem J. 1992 Apr 1;283 (:1–19. [PubMed]
- Ostrowski J, Kjelsberg MA, Caron MG, Lefkowitz RJ. Mutagenesis of the beta 2-adrenergic receptor: how structure elucidates function. Annu Rev Pharmacol Toxicol. 1992;32:167–183. [PubMed]
- Kobilka BK, Kobilka TS, Daniel K, Regan JW, Caron MG, Lefkowitz RJ. Chimeric alpha 2-,beta 2-adrenergic receptors: delineation of domains involved in effector coupling and ligand binding specificity. Science. 1988 Jun 3;240(4857):1310–1316. [PubMed]
- Merendino JJ, Jr, Speigel AM, Crawford JD, O'Carroll AM, Brownstein MJ, Lolait SJ. Brief report: a mutation in the vasopressin V2-receptor gene in a kindred with X-linked nephrogenic diabetes insipidus. N Engl J Med. 1993 May 27;328(21):1538–1541. [PubMed]
|